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The Regulation of Toothpaste
Food is the very sustenance of life for humans. Perhaps no body
structures are more crucial to human consumption of food than our
teeth. The teeth serve to break up larger pieces of food into smaller,
more digestible bits that our bodies can use. Teeth are always sub-
ject to decay from the various food particles that are constantly
brushed against them, occasionally left undetected there for several
hours. Humankind invented toothpaste for a variety of reasons, the
most important of which is the prevention of this tooth decay. Oth-
ers include the freshening of breath, and the whitening or strength-
ening of the teeth. Usually, we, the buying public, do not see this
product until it is in its familiar plastic tubing at the supermarket,
complete with an easy-to-read (usually) label and brand name con-
veniently on the front. However, before their product reaches the
shelves, manufacturers of toothpaste in this country are regulated
by the Food and Drug Administration with various practices de-
signed to protect the public. These practices include ocial FDA
standards on toothpaste safety and eectiveness, as well as regula-
tion of how much and which kind of ingredients are permitted in
the formula. There are also strict standards involving the labeling
of the toothpaste, as established in the FDA's nal monograph for
anticaries drug products. Lastly, a brief look at toothpaste regu-
lation in other countries will serve to show the relative severity of
regulation practiced by the FDA.
1Classication of Toothpaste Under the 1938 Act
Since its enactment in 1938, administration of the Federal Food
Drug and Cosmetic Act has fallen on the Food and Drug Ad-
ministration (FDA). The 1938 Act brought cosmetics and medical
devices under the statute, in addition to the foods and drugs already
within its scope before 1938. Under the Act, foods are regulated dif-
ferently than cosmetics, which are in turn dealt with dierently than
drugs. The placing of toothpaste into one of these three categories
is more complex than it rst may seem. Section 321 of the Act
denes food as (1) articles used for food or drink in man or other
animals, (2) chewing gum, and (3) articles used for components of
any such article.1 Clearly, toothpaste does not fall into this category.
Humans and other animals do not eat this product, nor do they in-
tentionally consume any of it at all. The next category in the Act is
drugs, which are dened briey as (A) any article recognized in any
of the ocial national drug publications or a supplement thereof,
and (B) articles intended for use in the diagnosis, cure, mitigation,
treatment, or prevention of disease in man or other animals, or (C)
articles (other than food) intended to aect the structure or any
function of the body.2 Subpart (B) of this denition makes a good
case for the inclusion of toothpaste, as one of the main purposes of
toothpaste is the prevention of tooth decay, known as caries. Un-
der the statute, toothpaste is likely ruled out of the medical device
category because it achieves its primary intended purposes through
chemical action within the body.3 Lastly, there is the
21 U.S.C. x321(f) (1938)
21 U.s.c. x321(g) (1)
21 U.s.c. x321(h)
2cosmetic category, which also could include toothpaste. These
are dened as articles intended to be rubbed, poured, sprinkled, or
sprayed on, introduced to, or otherwise applied to the human body
for cleansing, beautifying, promoting attractiveness, or altering the
appearance. Again, toothpaste could fall under this category since
it could be said that its purposes are cleansing and beautifying the
teeth.
The FDA has spoken in the Federal Register as to how the dis-
tinction between a drug and a cosmetic is to be determined. The
FDA has stated that the intended use of a product is the primary
determining factor as to whether a product is a drug, a cosmetic, or
both.4 This intended use may be inferred from the product's label-
ing or advertising, as well as from any other relevant factor, includ-
ing the presence of particular ingredients.5 The presence of a known
therapeutic ingredient can cause a product to be regulated as a drug,
even in the absence of drug claims. Along these lines, the FDA has
decided that all toothpastes or other dentiftices which contain uo-
ride will indeed be regulated as drugs, regardless of whether or not
any drug claims have been made.6 The Agency reasons that uoride
is widely accepted as an anti-cavity agent by the dental products
industry and consumers, and because uoride aects the structure
of the tooth.7 The Agency has also stated that intended use can be
demonstrated by evidence that (1) drug-like eects in a large pro-
portion of users are foreseeable by the reasonable manufacturer, (2)
consumers use the product predominantly for its signicant phar-
macological eects, or (3)
~ 59 Fed. Reg. 5226, 5227 (1994)
~ ~ National Nutritional Foods Association V. Mathews, 557 F.2d 325,
334 (2d Cir. 1977)
59 Fed. Reg. 6084, 6088 (1994)
60 Fed. Reg. 41453 (1995)
3manufacturers know that the product will be used for these drug-
like eects.8 This drug classication reects a general decision on
FDA's part that toothpastes are indeed used primarily for the pre-
vention of disease; in truth, such products are labeled as anticaries
agents in all versions of the FDA's monograph for such products,
and nearly all tubes of toothpaste contain somewhere on the label
the message that the product ghts cavities and/or prevents tooth
decay.
This explanation would seem to leave open the possibility that a
toothpaste could be regulated at least partially as a cosmetic if its
main claims were for the beautication of the teeth, and not the pre-
vention of caries. The FDA has ruled that if a product is intended
for use as both a drug and as a cosmetic, it must comply with all
of the specications found for the drug within the FDA nal mono-
graph, plus it must bear the applicable labeling for cosmetic use
in conformity with 21 U.S.C. x362.~ However, achieving a cosmetic
status for any type of toothpaste or dentifrice would be a dicult
task, since most such products do contain some amount of uoride,
a proven cavity ghter, and would thus automatically be regulated
as a drug. The FDA has also explained that, in the case of tooth-
pastes, the cosmetic function of attractive teeth is accompanied by
the drug mechanism of preventing cavities, and it has thus prohib-
ited cosmetic status on these grounds. One can only surmise that it
would still be possible to have a toothpaste regulated as a cosmetic,
but this would not be a toothpaste in the traditional sense. A cos-
metic toothpaste would likely have to contain no known therapeutic
or drug-like ingredients, and be marketed, labelled, intended, and
primarily used as a cosmetic. An example might be a toothpaste
oered
~ 58 Fed. Reg. at 47611 (1993)
~ 59 Fed. Reg. 5226, 5227 (1994)
4solely to smokers to whiten their stained teeth, with no anti-
caries indications. An additional comment on the label specifying
that the product is not an anti-cavity agent and that another anti-
caries toothpaste should be used in conjunction with this product
could only help the cause. It is unclear how such actions would
fare in court, since the ingredients approach to classication has not
been tested adequately nor applied consistently by courts or by the
FDA.10
Are Certain Toothpastes New Drugs?
In order to better protect the public from drugs that are unsafe
or ineective, the FDA strictly limits the drugs that may be entered
into interstate commerce without rst being reviewed and approved
by the Agency. This FDA power, however, does not extend over all
drugs; drugs that are not dened as new drugs under the statute
may be introduced and marketed without premarket Agency review
or approval. However, in the case of new drugs, a New Drug Applica-
tion (NDA) must be submitted to and approved by the FDA before
the product may be legally marketed. The FDA, in determining the
status of an NDA, must be satised that the new product is both
safe and eective before it will approve the application. The Act
denes a new drug as Any drug...the composition of which is such
that such drug is not generally recognized, among experts qualied
by scientic training and experience to evaluate the safety and eec-
tiveness of drugs, as safe and eective for use under the conditions
prescribed.., in the labeling thereof.... Under
10 51 Food & Drug L.J. 243, 255 (1996)
21 U.S.C. x32l(p) (1938)
5these guidelines, a toothpaste which merely uses the same in-
gredients in the same combination as another, previously approved
toothpaste formula would not be classied as a new drug under the
statute. Thus, manufacturers of such a product would avoid having
to submit an NDA and could avoid FDA regulation as a new drug
entirely. However, since toothpastes have become widely used, man-
ufacturers have constantly sought new ingredients, and new combi-
nations thereof, in an eort to further dierentiate their product
from the myriad others on the market and to attract the consumer
to their brand because of its particular ingredients and abilities.
This has caused some potential problems in the FDA conferring
a much-unwanted new drug status upon certain toothpastes. In
U.S. v. Articles of Drug... Promise Toothpaste12, the court armed
that certain toothpastes are indeed new drugs under the 1938 Act.
The court explained that even if the component parts of a new
drug are generally recognized as safe or eective, the combination
of those parts may still be unsafe or ineective.13 Thus, quantities
of toothpaste containing this new combination of active ingredients
and introduced into interstate commerce without an approved NDA
were subject to forfeiture.14 An OTC drug be recognized as safe and
eective after combining two or more safe and eective active ingre-
dients only if the new drug meets the following three conditions: (1)
each active ingredient makes a contribution to the claimed eect(s),
(2) combining of the active ingredients does not decrease the safety
or eectiveness of any of the individual active ingredients, and (3)
the combination, when used under adequate directions for use and
12 826 F.2d 564 (7th Cir. 1987)
13 .I4~ at 3
14 j~ at 5
6warning against unsafe use, provides rational concurrent ther-
apy for a signicant proportion of the target population.15 In the
Promise Toothpaste case, the court, using these criteria, ruled that
Promise's combination of a single anticaries ingredient and another
active ingredient is a new drug subject to the NDA requirements of
the 1938 Act. According to the Promise Toothpaste case and the
regulation, for combination toothpaste products, the manufacturer
must likely get a new NDA approved for the product. Since this
process is time-consuming and costly, and could potentially lead to
denial of an NDA anyway, most manufacturers would like to avoid
this step. In order to avoid this classication as a new drug under the
statute, the manufacturer of a combination toothpaste must show
that each ingredient contributes to the claimed eects, and that the
combination does not make any of the individual components any
less safe or eective.16
Safety Regulations for Toothpaste
In the Federal Register of October 6,1995, the FDA established
its nal monograph for OTC anti-cavity drug products. This nal
monograph includes the conditions under which the products cov-
ered by the monograph will be considered safe and eective. In
ensuring the safety of toothpaste, the FDA has established a num-
ber of regulations, relating to the required testing procedures before
the product may be marketed, the size and type of packaging for
the product, and the necessary ingredients and warnings on the
15 21 C.F.R. x330.10(a) (4) (iv)
lb~ee U.S. v. Articles of Drug...Promise Toothpaste, 826 F.2d 564; ~ U.S. v. Seven Cardboard Cases...100
Capsules...With Codeine, 716 F.Supp. 1221, 1223
7label.
The nal monograph establishes two tests, one of which must me
met by any toothpaste product before it is considered safe to be on
the market for humans. Each product must satisfy either the enamel
solubility reduction test or the uoride enamel uptake test. Either
of the two tests is sucient to satisfy the safety requirement.17 The
procedures for these tests are readily available at the FDA oces
in Maryland. As part of these biological tests, the United States
Pharmacopeia uoride dentifrice reference standards and reference
standard stability proles (total uoride, available uoride ion, pH,
and specic gravity) must be used, and these too are available at the
FDA oces.18 Additionally, alternative tests may be used, provided
that the manufacturer petitions the FDA with the vital data of these
proposed tests and makes all required disclosures.19
In terms of toothpaste packaging, the FDA is concerned with the
toxicity of uoride, an active ingredient in almost all toothpastes
due to its proven cavity-ghting power. Thus, the Agency has
placed a package size limitation on all dentifrice (toothpaste and
tooth powder) products. According to the nal monograph, such
products may not contain more than 276 milligrams of total uo-
rine per package.20 This requirement is what keeps toothpaste tubes
at their relatively small size. Additionally, the FDA also thought
it important to avoid exposure of water and other moisture to cer-
tain toothpastes. Thus, all uoride powdered toothpastes must be
packaged in a tight container. This is dened in
'~ 60 Fed. Reg. 52474(1995), as codied in 21 C.F.R. x355.70 (a) (1995)
18 x355.70(b)
19 x355.70(c)
20 60 Fed. Reg. 52474(1995), 21 C.F.R. x355.20(a) (1) (1995)
8the section as a container that protects the contents from con-
tamination by extraneous liquids, solids, or vapors, from loss of the
article, and from eorescence, deliquescence, or evaporation under
ordinary conditions of handling, shipment, storage, and distribu-
tion. Such a container must also be capable of tight closure.21 The
exception is that package size limitations do not apply to anticaries
drug products marketed for professional oce use only.22 x355.60(b)
provides that the labeling of products marketed to health profes-
sionals in package sizes larger than those allowed in x355.20 must
contain on the label For Professional Use Only and This product
is not intended for home or unsupervised consumer use. Note also
that dentifrices, along with dermatologics and insulin, are the only
OTC drugs not subject to the FDA's tamper-resistant packaging
requirement.23
The nal monograph for anticaries drug products also requires a
number of disclosures to be prominently on the label of the product
to ensure public safety. These requirements will be discussed in a
later section, under Labeling.
Eectiveness Regulations for Toothpaste
The FDA also dealt with ensuring the eectiveness of toothpaste
in its nal monograph for anticaries drug products. Eectiveness is
dened as a reasonable expectation that, when used under adequate
directions and warnings, a signicant proportion of the target
21 x355.20(b)
22 x355.20 (a) (3)
23 47 Fed. Reg. 50442(1982)
9population will show signicant relief of the type claimed.24 Much
as with the safety requirements, all toothpaste products must meet
the animal caries reduction test before being marketed to humans.25
In other words, the ingredients in every tube of toothpaste we see
must rst have been proven at least to reduce tooth decay in ani-
mals. This was a new requirement in the nal monograph, and as
a result, all products are expected to comply with this requirement
by June 30, 1997.26 As with the required safety tests, x355.70(c)
allows alternative eectiveness tests with the proper petition and
approval. Additionally, the OTC Panel concluded in 1980 that if
certain analytic and biologic tests are performed, and acceptable
results are achieved, then clinical testing is not required because
extensive clinical testing has previously been performed on the ef-
fectiveness of toothpaste products. The acceptable results are those
obtained from other toothpastes that have already been proven to
be clinically eective.27 Note that if a toothpaste contains a combi-
nation of ingredients, as discussed above, then new clinical testing
will be required to conrm the safety and eectiveness of this com-
bination drug.
Labeling of Toothpaste
There are several regulations in the nal monograph for anticaries
drugs dealing with
24 U.S. v. Articles of Drug...Promise Toothpaste, 826 F.2d
564 (7th Cir. 1987)
25 60 Fed. Reg. 52474 (1995), 21 C.F.R. x355.70(a) (1995)
26 61 Fed. Reg. 65944, 65945 (1996)
27 45 Fed. Reg. 20677 (1980)
10the labeling of the products, some of which apply only to tooth-
pastes, and others which apply more generally to all anticavity drug
products (i.e. dentifrices, mouthwashes, oral rinses and gels, etc.).
The rst and perhaps most basic is the statement of identity, which
must include the established name of the toothpaste, and must
clearly identify the product as: anticavity uoride (select one of
the following as appropriate: dentifrice, toothpaste, tooth polish,
or tooth powder; (optional: dental)).28 The regulation provides the
denition of dentifrice as An abrasive-containing dosage form (gel,
paste, or powder) for delivering an anticaries drug to the teeth. ~ As
regards products which are arguably either cosmetics or drugs (such
as some toothpastes discussed earlier), the FDA does not believe it
necessary to include the phrase drug product on the label because
the requirements for labeling only apply to drugs. If the product is
indeed intended to be both a drug and a cosmetic, it must comply
with the drug labeling requirements as well as those for cosmetics,
found in 21 U.S.C. x362.~
Next, all toothpaste labels must list Indication, followed by: Aids
in the prevention of dental (select one of the following: cavities, de-
cay, caries (decay), or caries (cavities). II)1131 Other non-misleading
statements may be included under Indication provided that they de-
scribe this indication found in x355.50(b).
Toothpaste labels must also include warning statements. 21
C.F.R. x355.50(c)(1 )(1995) provides that all uoride dentifrices
(toothpastes and tooth powders)
28 60 Fed. Reg. 52474, 52508(1995), as codied in 21 C.F.R. x355.50 (a)
(1995)
29 x355.30(e)
30 59 Fed. Reg. 5226, 5227(1994)
31 21 C.F.R. x355.50(b) (1995)
11must include the following statement: Keep out of the reach of
children under 6 years of age. A recent addition to this warning is:
If you accidentally swallow more than used for brushing, seek profes-
sional assistance or contact a Poison Control Center immediately.32
This is due to the constant controversy over the toxicity of uoride
in larger amounts than are normally ingested during brushing of the
teeth.
21 C.F.R. x355.50(d) deals with directions on toothpaste labels.
The heading must be marked Directions, and the required directions
dier slightly depending on the total uoride concentration of the
active ingredients. See section labeled Ingredients for further dis-
cussion. According to the nal monograph, the following statement
must also be prominently placed on the principal display panel: IM-
PORTANT: Read directions for proper use.~
(1) For toothpastes with a theoretical total uorine concentration
of 850 to 1150 parts per million (ppm), the directions must read
Adults and children 2 years of age and older:
Brush teeth thoroughly, preferably after each meal or at least
twice a day, or as directed by a dentist or doctor. Instruct children
under 6 years of age in good brushing and rinsing habits (to min-
imize swallowing). Supervise children as necessary until capable of
using without supervision. Children under 2 years of age: Consult
a dentist or doctor.3' The word minimize is a recent change from
the tentative nal monograph, and was changed because, after per-
forming studies on young children, the OTC panel concluded that
children will often tend to swallow minute amounts of toothpaste
during normal brushing.
32 61 Fed. Reg. 52285, 52287 (1996)
~ x355.55
12The previous version of the monograph spoke of prevention of
swallowing instead of simply minimization, and the Panel concluded
that there was no need to worry parents who observe their children
swallowing small amounts of uoride3 ~
(2) For toothpastes with a theoretical total uorine concentration
of 1500 ppm, the directions include the same rst sentence, but then
also must include the following:
Instruct children under 12 years of age in good brushing and rins-
ing habits (to minimize swallowing). Supervise children as necessary
until capable of using without supervision. Children under 6 years of
age: Do not use unless directed by a dentist or doctor.36 These mi-
nor changes deal only with raising the recommended age for children
to use products with such high concentrations of uorine, because
the toxicity and danger of uorosis is increased in younger children.
An optional direction statement for such high-concentration uoride
toothpaste products is: Adults and children over 6 years of age may
wish to use this extra-strength uoride dentifrice if they reside in
a nonuoridated area or if they have a greater tendency to develop
cavities.37
(3) For powdered toothpastes with a theoretical total uorine
concentration of 850 to 1150 ppm, the required directions contain
much the same age restrictions as the higher-concentration tooth-
pastes in part (2) above, along with specic directions on how to
use the powdered pastes themselves.~
In the earty to mid I 980's, Crest and Colgate were the rst to
introduce 'Tartar Control
~ 60 Fed. Reg. 52474, 52488(1995) 36 355.50(d) (ii)
~ x355.50(f) (2)
~ x355.50(d) (iii)
13toothpaste, making anti-tartar and anti-plaque claims about their
products. The FDA says that it has not objected to plaque reduc-
tion claims when the reduction of plaque is based on the abrasive
action of the dentifrice during brushing but has objected recently
where such claims are attributed to one or more of the toothpaste's
active ingredients. ~ The Agency did not take action against anti-
tartar toothpastes when they rst were marketed in 1983, viewing
such claims as purely cosmetic, rather than drug claims subject to
strict regulation.~ This lack of action was based on the fact that
supragingival (above the gumline) tartar does not lead to disease,
while subgingival tartar does. Thus, reasoned the FDA, a tooth-
paste that claims to reduce supragingival tartar is not making a
disease-prevention claim, but rather merely a cosmetic one. There-
fore, the FDA OTC Committee has ruled that anti-tartar products
should say on the label that the substances only aect supragingival
tartar and have no therapeutic eect on gingivitis (gum disease) if
the manufacturer wants these claims to have purely cosmetic status.
Further, the Agency will consider all unqualied tartar claims to be
drug claims.41
All toothpastes, like other OTC drugs, are subject to the other
labelling requirements of 21 U.S.C. x352(1938) as well. x352(a) ex-
plains that a drug is deemed misbranded, and thus may not be
entered into interstate commerce, if its labeling is false or mislead-
ing in any particular. This is why we do not see toothpastes on the
market which claim on the label to guarantee no cavities during the
user's lifetime, or other similarly ridiculous claims. x352(b) indi-
cates that the package containing the drug (in this case, the pump
or tube
~ The Rose Sheet, Mar. 18, 1996
40 The Pink Sheet, November 13, 1989
41 The Rose Sheet, April 17, 1995
14of toothpaste) must include the name and address of the manu-
facturer, packer, or distributor42 and an accurate statement of the
weight, measure, or numerical count of the contents of the package4 ~
Thus, toothpastes usually contain on the label the net weight of the
tube or pump.
Ingredients of Toothpaste
21 U.S.C. x352 (1938), dealing with misbranded drugs or devices,
also contains a nal requirement that a drug is deemed misbranded
unless it contains the established name of the drug (i.e. the active
ingredient), or, in the case of combination drugs discussed earlier,
the established name and quantity of each active ingredient. The -
nal monograph for anticaries drug products provides guidance as to
what drugs and dosages of each will be accepted by the FDA as the
active ingredient for toothpastes. 21 C. F. R. x355.10(1995) provides
for three dierent acceptable active ingredients. First, sodium uo-
ride may be used, with.188 to.254 percent sodium uoride (in paste
or powdered form), with slightly higher requirements of available u-
orine ion in the powder than in the paste. Secondly, sodium monou-
orophosphate has also been approved by the Panel, in a.654 to.884
percent concentration for dentifrices containing average amounts of
uorine, or in a 1.153 percent concentration for high-uorine for-
mulas. Lastly, the OTC Panel has also approved toothpastes with
stannous uoride as the active ingredient, in a.351 to.474 percent
concentration, and with lower available uorine ion requirements in
formulas containing
42 x352(b) (1) (1938)
~ x352(b) (2)
15calcium pyrophosphate than in those using a dierent element as
an abrasive.
There has also been much regulation regarding the use of col-
ored dyes in toothpastes. D&C Red No. 8 and No. 9, which were
approved for use in dentifrices in I 983~, were then prohibited from
being added to dentifrices and mouthwashes after January 5, 1 987~~
D&C Red No. 33 and No. 36 are similarly prohibited from use in
mouthwashes and toothpastes, though they have been approved for
other ingested drugs.47 FD&C Red No. 40, however, has been ap-
proved for use in dentifrices that are cosmetics~ and eventually for
cosmetics generally ~. Similarly, D&C Orange No. 5 has been ap-
proved for drug and cosmetic dentifrices.~ D&C Orange No. 17 has
been approved for use in dentifrices, but only at not more than.002
percent of the pure dye by weight of the dentifrice.51 FD&C Yellow
No. 5 may also be used in dentifrices that are drugs and cosmetics,
and the labels of these dentifrices need not necessarily declare the
presence of this dye, as must other products.52
Another ingredient permitted to be used in the manufacture of
toothpastes is mica. The FDA ruled in 52 Fed. Reg. 29664(1987)
that it is safe to use mica in toothpastes that are
~ x355.10 (a) (1)|(2) (1995)
~ 48 Fed. Reg. 13976, 13978(1982)
46 51 Fed. Reg. 43877(1986)
~ 53 Fed. Reg. 33110, 33120(1988) and 53 Fed. Reg. 29024, 29031 (1988)
48 39 Fed. Reg. 28278(1974)
~ 39 Fed. Reg. 44198(1974)
~ 49 Fed. Reg. 31852(1984)
~ 48 Fed. Reg. 5262, 5264(1983)
52 50 Fed. Reg. 23815, 23817(1985)
16cosmetics as well as drugs, in response to a petition from the
Procter and Gamble company. Sodium is also permitted (see In-
gredients), and toothpastes and mouthwashes are exempt from the
labeling requirement (listing the amount of sodium in the product)
since these products are not intended for oral ingestion. At this time,
insucient data has been brought to the attention of the FDA as to
the absorption of sodium when these products are used to warrant
a sodium labeling requirement.~
The Fluoride Issue
A specic ingredient found in toothpastes that has come under
much debate due to its toxicity is uoride. Humans, mostly children,
are at risk of developing uorosis of the teeth if exposure to uoride
is not curbed at some point, which can leave teeth greatly discolored
and stained. The FDA, using a cost-benet analysis, thus feels that
children under 6 should not use toothpastes exceeding 1150 ppm of
total uoride.5' The Agency, however, has determined that a 1500-
ppm theoretical total uoride level is safe for children over 6 and for
adults (based on two clinical studies), approving an NDA for such an
extra-strength uoride dentifrice in 1986. However, since uorosis is
increasing among children in this country, the FDA cautions against
those below the age of 6 from using such products. The Agency
has also ruled that uoride levels above I 500 ppm have not been
proven safe and eective, and thus they were excluded from the nal
monograph for anticaries drug
~ 61 Fed. Reg. 17798, 17800(1996)
~ 60 Fed. Reg. 52474, 52479(1995)
17Id.
56 Id. at 52483
products55 The FDA, after extensive testing, has also stated that
presently there is not enough evidence to show that a low-uoride
dentifrice is safe and eective for children 2 to 6 years old, or to de-
termine the proper uoride concentration for such a low-level denti-
frice, and thus these too have been left out of the nal monograph.
Note as well that, despite this ongoing debate, the nal monograph
for anticaries drug products still contains no requirement that tooth-
pastes containing uoride label the quantity of uoride within the
product. ~
International Regulation of Toothpaste
Many of the same issues facing the FDA in America are also
being faced currently by other advanced countries as they attempt
to protect their citizens from the possible evils of misbranded or
poorly formulated drugs. This issue is especially important with a
product such as toothpaste, which is placed in the mouth and has
the potential to be ingested. England, for instance, recently went
through an incident which may lead to increased labeling regula-
tion of uoride-containing toothpastes. Colgate-Palmolive agreed
to make a settlement payment to a family whose child had his teeth
permanently discolored as a result of the same uorosis problem
that has concerned the FDA in this country. In fact, now more than
300 British families are making similar claims against
18toothpaste manufacturers.57 As a result of these claims, lead-
ing supermarket chains in England are considering introducing new
uoride-free toothpastes themselves and adding warnings against
swallowing the product on toothpaste labels, which do not currently
exist. Current labeling requirements in England require instructions
that only a pea-sized amount should be used, and that children un-
der 7 years of age should be supervised when brushing their teeth.55
Additional regulations require that manufacturer's claims merely
be not misleading, since toothpastes fall under cosmetic and not
medical regulations.55 A spokesman for the Department of Health,
however, says there are no plans to change the current level of gov-
ernmental regulation.
The European Union, facing similar problems, strictly regulates
cosmetic products, which include toothpastes. These regulations,
much like in America, focus largely on the composition and label-
ing of such products. The EU has also established a post with the
power to receive complaints from any citizen of the EU with a con-
sumer issue.~ Canada has similar standards for which claims may
be made on labels, and for strengths of sodium uoride, acidulated
phosphate uoride, and stannous uoride. In Canada, manufactur-
ers may make various cavity-prevention claims, but several warnings
are required on oral care products. These include warnings against
swallowing the product, and that children
~ Jackson, Linda, Toothpaste to carry chemical warning, The Sunday Telegraph,
London, Sunday Dec. 1, 1996
~ Bloor, Caroline, Consumer News: Brushing Up on a Whiter Smile,
The Daily Telegraph, London, Monday, Feb. 26, 1996
60 Lansman, Nicholas, Consumer Protection in the EU, ~ap Perfumery
& Cosmetics, Monday, July 1, 1996
19should be supervised when using toothpaste.61
In Singapore, June 1997 marks the deadline after which all cos-
metic products, including toothpastes, will have to bear content
labels for the rst time. These measures are designed to protect
members of the public from using products containing ingredients to
which they are allergic, as well as to help doctors determine which
substances cause allergic reactions in their patients. All cosmetic
products in Singapore will also have to contain batch numbers for
the rst time.62 The country's Health Ministry says it will be illegal
to manufacture, import, sell, or supply any cosmetic product that
does not meet these new specications.
Conclusion
It can be seen that the FDA indeed imposes rather strict regu-
lations on toothpaste products in this country. For the purpose of
fullling its mission to protect the public from unsafe and ineec-
tive products, uoride toothpaste is regulated as a drug under the
1938 Food Drug and Cosmetic Act. The FDA attempts to ensure
the safety of toothpastes by requiring certain testing, and by regu-
lating the ingredients used in the product, as well as the packaging
and the warnings thereon. The Agency also uses testing procedures
and various standards to be sure the toothpastes on the market are
eective. The OTO drug review resulted in a nal monograph for
anticaries drug products in late I 995, and this
61 ~ Oral Care Products: Canada{New Labeling Regulations, Sunday, Sep.
1, 1996
62 All cosmetic products to show contents, some to be licensed, Singapore Straits Times,
Saturday, June 15, 1996
20monograph provides the three acceptable active drugs for use in
toothpaste products, as well as other allowable ingredients. Strict
labeling requirements are also promulgated in the C.F.R. for tooth-
pastes, to ensure that the public is given all the information deemed
necessary by the OTC Panel. Finally, it is apparent that the FDA
imposes similar, if not more stringent, requirements on its tooth-
paste manufacturers than other countries impose on theirs, mostly
dealing with the labeling and composition of toothpaste products.
One can only hope that the stringency of these requirements will
continue to protect the American people from a major toothpaste
scare, as have occurred with various other consumer products over
the last few decades.
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